Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 4Terminated 3Recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2NETWORK 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Non-Muscle Invasive Bladder Neoplasms 3Urinary Bladder Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

pembrolizumab 184Carboplatin 132Paclitaxel 101Cisplatin 101Gemcitabine 86Pemetrexed 79durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 41Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × BCG Vaccine × Clear all
NCT03711032 2026-05-01

MK-3475-676

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
1,397 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05981131 2026-04-29

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

ImmunityBio, Inc.

Active not recruiting
6 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

AstraZeneca

Phase 3 Active not recruiting
1,018 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04165317 2026-01-22

CREST

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡